Skip to Content
Stock Strategist Industry Reports

What a Biden Presidency Could Mean for Drug Pricing

Reforms are likely to be moderate, and we don’t expect significant changes in 2020.

We think Joe Biden’s moderate position and nomination as the Democratic presidential candidate reduces the likelihood of significant drug pricing policy changes, in spite of more-aggressive reform recommendations from the Biden-Sanders unity task force. This forecast comes amid uncertainty around the bigger-picture healthcare issue, as the future of the Affordable Care Act is being debated at the U.S. Supreme Court level.

The low probability of drug pricing policy changes also reduces the likelihood of a major policy-related impact on drug innovation. We see a less than 10% probability of a "Medicare for All" system within the next decade, and we don’t include it in our analysis. Such a system would reduce U.S. drug prices with the negotiating power of a one-payer system, but odds are likely even longer now that U.S. Sen. Bernie Sanders is no longer in the running for the Democratic nomination.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.